Preparation of sustained-release dosage form of Venlafaxine HCl using liquisolid technique

被引:12
|
作者
Khanfar, M. [1 ]
Salem, M. Sheikh [1 ]
Kaddour, Faiza [1 ]
机构
[1] Jordan Univ Sci & Technol, Fac Pharm, Dept Pharmaceut Technol, Irbid 22110, Jordan
关键词
Eudragit RS PO; liquisolid; sustained release; Venlafaxine HCl; DISSOLUTION RATE; IN-VITRO; TABLETS; ENHANCEMENT; INDOMETHACIN; MICROSPHERES; FORMULATION; TECHNOLOGY; DELIVERY; MATRICES;
D O I
10.3109/10837450.2012.757785
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Context: The aim of this study is to control the dissolution rate of Venlafaxine HCl. Objective: To prepare sustained release tablets of Venlafaxine HCl. Material and methods: Different liquisolid formulations, liquid vehicles, drug concentration in the liquid medication and different ratios of carrier to coating material (R) were prepared. The prepared powders were characterized for possible interactions between drug and excipients using differential scanning calorimetry, X-ray, Fourier transform infrared analysis and scanning electron microscopy. Powder flowability was also evaluated, then they are compressed at different compression forces, and the compressed tablets were evaluated for their mechanical properties and dissolution profile. Results: Release results show that sustained release behavior can be obtained from liquisolid formulation containing Tween 80 as liquid vehicle. Discussion: Many factors affect the retardation effect of Venlafaxine HCl such as the type of liquid vehicle, drug concentration in the liquid medication and R. The mechanism of the in vitro release profiles was found to be mainly controlled by diffusion and polymer relaxation. Conclusion: Sustained release formulation of Venlafaxine HCl was attained using the liquisolid technique.
引用
收藏
页码:103 / 115
页数:13
相关论文
共 50 条
  • [41] KINETICS OF A NALTREXONE SUSTAINED-RELEASE PREPARATION
    CHIANG, CN
    HOLLISTER, LE
    KISHIMOTO, A
    BARNETT, G
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1984, 36 (05) : 704 - 708
  • [42] STUDIES ON SUSTAINED-RELEASE DOSAGE FORMS .1. PREPARATION AND BIOAVAILABILITY OF INDOMETHACIN SUPPOSITORIES
    UMEDA, T
    MATSUZAWA, A
    YOKOYAMA, T
    KURODA, K
    KURODA, T
    [J]. CHEMICAL & PHARMACEUTICAL BULLETIN, 1983, 31 (08) : 2793 - 2798
  • [43] EXPERIENCES ON A SUSTAINED-RELEASE PROCAINAMIDE PREPARATION
    RUOSTEENOJA, R
    TORSTI, P
    SOTHMANN, A
    [J]. CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1973, 15 (10): : 707 - 712
  • [44] Preparation of the Sustained-Release Microcapsules of Baicalin
    WANG Yu-mei1
    2.School of Chemical Engineering
    [J]. Medicinal Plant, 2011, (07) : 42 - 45
  • [45] AN EXAMPLE OF PHARMACEUTICAL STUDIES ON SUSTAINED-RELEASE DOSAGE DESIGN
    YAMAKAWA, I
    SHIMOMURA, M
    HATTORI, T
    WATANABE, S
    TSUTSUMI, J
    SHINODA, A
    MIYAKE, Y
    [J]. JOURNAL OF PHARMACOBIO-DYNAMICS, 1984, 7 (02): : S38 - S38
  • [47] Parenteral sustained-release dosage forms of butorphanol for dogs
    Chang, HC
    Li, LC
    Marsh, KC
    Tian, Y
    Grischeau, D
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1999, 176 (02) : 147 - 156
  • [48] APPLICATION OF SOLID DISPERSIONS OF NIFEDIPINE WITH ENTERIC COATING AGENT TO PREPARE A SUSTAINED-RELEASE DOSAGE FORM
    HASEGAWA, A
    NAKAGAWA, H
    SUGIMOTO, I
    [J]. CHEMICAL & PHARMACEUTICAL BULLETIN, 1985, 33 (04) : 1615 - 1619
  • [49] NEW SUSTAINED-RELEASE FORM OF LITHIUM SULFATE
    VENTOURAS, K
    DICK, P
    BURI, P
    [J]. SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, 1973, 103 (24) : 878 - 881
  • [50] The cytisine-enriched poly(3-hydroxybutyrate) fibers for sustained-release dosage form
    Czerniecka-Kubicka, Anna
    Skotnicki, Marcin
    Gonciarz, Weronika
    Zarzyka, Iwona
    Jadach, Barbara
    Lovecka, Lenka
    Maternia-Dudzik, Karolina
    Kovarova, Miroslava
    Pyda, Marek
    Tutka, Piotr
    Sedlarik, Vladimir
    [J]. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2023, 245